SCHEMBL21612907

SCHEMBL21612907

CC(C)(C)OC(=O)c1ccc(OC2CCN(C(=O)OCc3ccccc3)C2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
CYP2C19 P33261 1/20 0.47
PDE4B Q07343 2/20 0.46
HTT P42858 1/20 0.46
LMNA P02545 1/20 0.46
GPR119 Q8TDV5 3/20 0.44
LNPEP Q9UIQ6 1/20 0.44
PDK1 Q15118 1/20 0.43
PDK2 Q15119 1/20 0.43
PDK3 Q15120 1/20 0.43
PDK4 Q16654 1/20 0.43
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
PIK3CD O00329 1/20 0.43
FAAH O00519 1/20 0.43
EPHX2 P34913 1/20 0.43
BCHE P06276 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21612929 0.95 SMN1; SMN2 (0.53) USP30SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL15375880 0.92 USP30 (0.55) USP30LMNAGPR119JAK2JAK1
SCHEMBL15375881 0.92 USP30 (0.55) USP30LMNAGPR119JAK2JAK1
SCHEMBL15377844 0.92 USP30 (0.55) USP30LMNAGPR119JAK2JAK1
SCHEMBL19725050 0.85 S1PR3 (0.48) USP30SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL23475143 0.84 USP30 (0.58) USP30GPR119JAK2JAK1
SCHEMBL6929071 0.84 USP30 (0.53) USP30HTTGPR119JAK2JAK1
SCHEMBL3066778 0.84 USP30 (0.49) USP30SMN1; SMN2NPC1RAB9ACYP2C19
SCHEMBL16187531 0.83 ACACB (0.54) USP30PDE4B
SCHEMBL18176134 0.83 ACACB (0.54) USP30PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-01-03 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2021-09-16 US disclosed
EP-3819305-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2021-05-12 EP disclosed
CN-112543764-A Amide compound with BET proteolysis induction effect and medical application thereof 田边三菱制药株式会社 2021-03-23 CN disclosed
WO-2020009176-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF 田辺三菱製薬株式会社 2020-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542273-B2 Amide compound having bet proteolysis-inducing action and medicinal application thereof BET1, BRD4, PHKB USP30 587/4885SMN1; SMN2 4500/4885NPC1 3288/4885
US-20210284654-A1 AMIDE COMPOUND HAVING BET PROTEOLYSIS-INDUCING ACTION AND MEDICINAL APPLICATION THEREOF BET1, BRD4, PHKB USP30 590/4885SMN1; SMN2 4459/4885NPC1 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.